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Background: Presently, CD133 is one of the hottest markers to characterize cancer stem cells and KAI1/CD82 is
reported as an important marker for the metastasis and prognosis of many cancers. The purpose of our study is to
explore the relationship between cancer stem cells (CSCs) marked by CD133 and KAI1/CD82 expression and the
clinicopathological characteristics of patients with laryngeal squamous cell carcinoma (LSCC).
Methods: Immunohistochemical analysis was used to detect the expression of CD133 and KAI1/CD82 in 83 archival
surgical specimens of human LSCC and 83 cases of normal laryngeal tissues.
Results: In LSCC, positive rates of 49.4% and 41.0% were obtained for CD133 and KAI1/CD82, respectively. The
expression of CD133 in LSCC tissues was significantly higher than that in normal tissues (P < 0.001), and the
expression of CD133 was positively associated with pTNM stage (P = 0.005), pathological grade (P = 0.001), and
lymph node metastasis (P < 0.001). The reduced expression of KAI1/CD82 was present in LSCC tissues. The positive
rate of KAI1/CD82 expression was negatively correlated with pTNM stage (P = 0.014), pathological grade (P < 0.001),
and lymph node metastasis (P = 0.007). A correlation analysis showed that there was a negative relationship
between the expression of CD133 and KAI1/CD82 protein in LSCC tissues (P < 0.001). By Kaplan-Meier analysis, the
expression of CD133 was negatively correlated with overall survival (OS) (log-rank = 40.949, P < 0.001) and disease-
free survival (DFS) (log-rank = 39.307, P < 0.001) time of LSCC. The expression of KAI1/CD82 was positively correlated
with OS (log-rank = 40.279, P < 0.001) and DFS (log-rank = 39.271, P < 0.001) time of LSCC. Cox regression analysis:
the expression of CD133 and KAI1/CD82, and pTNM stages were independent prognostic factors of LSCC (P < 0.05).
Conclusions: Thus the detection of CD133 and KAI1/CD82 proteins may be used as a potential indicator of LSCC
prognosis.Background
In the United States, laryngeal carcinoma accounted for
approximately 0.82% of new cancer diagnoses and 0.40%
of all cancer deaths in 2012 [1]. The major pathological
type of laryngeal cancers is squamous cell carcinoma, ac-
counting for 99% of laryngeal malignant tumors. Although
rapid progress has recently been made in treatment,
the prognosis for patients with laryngeal squamous cell* Correspondence: honghongwuwu@sohu.com
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reproduction in any medium, provided the orcarcinoma (LSCC) remains unsatisfactory. A major prob-
lem in finding treatments is the frequent resistance to
drugs which emerges. This is linked to the development
and maintenance of a small population of tumor cells,
termed cancer stem cells (CSCs). These cells have the
properties of self-renewal, proliferation, and multilineage
differentiation and are responsible for sustaining the
tumor [2] and are also thought to initiate tumor me-
tastasis and therapy-resistance [3,4]. A commonly in-
vestigated potential CSC marker is CD133 (also known as
prominin-1), a 120 kDa five transmembrane domain cell
surface glycoprotein, which was initially considered to
be one marker of hematopoietic stem cells [5,6]. Now,
CD133 may represent a putative cancer stem cell markerThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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breast cancer [9,10], gastric cancer [11,12], glioblastoma
[13], lung cancer [14,15], liver cancer [16,17], pancreatic
cancer [18], prostate cancer [19], and cholangiocarcinoma
[20].
Cancer metastasis involves multiple steps with a high
degree of complexity and requires the contribution of a
variety of molecules. The KAI1/CD82 gene was origin-
ally identified as a suppressor of metastasis of tumor in
prostate carcinoma [21]. Recent study has shown that
KAI1/CD82 gene expression is under-regulated in most
metastatic cancers [22]. It is a member of the tetraspan
transmembrane superfamily (TM4SF) and is a gene
located on human chromosome 11p11.2. KAI1/CD82
plays an important role in cell fusion, adhesion, migra-
tion, signaling, fertilization, differentiation, and invasion
[22-26]. Decreased KAI1/CD82 expression has been ob-
served to correlate with metastasis and poor prognosis
in many human solid tumors, such as prostate cancer
[27], lung cancer [28], breast cancer [29], colon cancer
[30], gastric cancer [31], liver cancer [32], and kidney
cancer [33].
To date, the correlation between CD133 and KAI1/
CD82 expression in LSCC is unknown. Therefore, this
study intends to investigate CD133 and KAI1/CD82 ex-
pression in the specimens of postoperative LSCC pa-
tients following primary laryngeal resection in order to
determine the correlation between the expression of




Paraffin embedded sections of 83 LSCCs and 83 normal
laryngeal tissues were obtained from the Department
of Pathology, the First Hospital Affiliated to Bengbu
Medical College from January to November 2003. We
excluded patients who received preoperative chemothe-
rapy or radiotherapy. Approval for this study was not
required by the ethical committee because the experi-
ments carried out did not relate to patient privacy, im-
pairment or treatment. The age of the patients ranged
from 43 to 84 years; the median age was 62.1 years. The
patients consisted of 75 males and 8 females. There were
43 cases whose tumors were < 2.0 cm in diameter and 40
cases whose tumors were ≥ 2.0 cm. Thirty were at grade
I, 47 were at grade II, and 6 were at grade III, according
to the grading system of the World Health Organization.
Fifty-one were of supraglottic type, 29 were glottic type,
and three were subglottic type. A total of 49 specimens
had no lymph node metastasis, whereas 34 specimens
showed lymph node metastasis. According to clinical
staging of pTNM, 21 were stage I, 32 were stage II, 22
were stage III, and 8 were stage IV.Immunohistochemical analysis
All samples were fixed in 10% buffered formalin and em-
bedded in paraffin. Four- micrometer thick tissue sections
were used for analysis. All sections were deparaffinized
and dehydrated with graded alcohol. Then, the sections
were washed for ten minutes in PBS at pH 7.2. The en-
dogenous peroxidase activity was quenched by incubation
in methanol containing 3% H2O2 for ten minutes at room
temperature, then heated for 30 minutes at 95°C to repair
the antigens and finally rinsed in PBS. After several
washes in PBS, sections were blocked with goat serum for
20 minutes at room temperature, and then incubated with
mouse monoclonal CD133 (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) and KAI1/CD82 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) primary anti-
bodies overnight at 4°C in a humidified chamber. The
slides were treated with polymer enhancer (reagent A) for
20 minutes at room temperature. Washing in PBS, the
slides were treated with goat anti-mouse antibody (reagent
B) for 30 minutes at room temperature. After a complete
wash in PBS, the slides were developed in freshly prepared
diaminobenzidine (DAB) solution for eight minutes, and
then counterstained with hematoxylin, dehydrated, air-
dried, and mounted.
Serial sections of LSCC were run in parallel with the
primary antibody replaced by PBS and rabbit IgG1 as
blank and negative controls.
Evaluation of score
Slides were reviewed independently by two observers to
evaluate the staining pattern of the protein under the
light microscope. Ten visual fields were randomly se-
lected from each slide. In scoring expression of CD133
and KAI1/CD82 proteins, both the extent and intensity
of immunopositivity were considered. The intensity of
the positive result was scored as follows: 0, negative; 1,
weak; 2, moderate; 3, strong. The extent of positivity was
scored according to the percentage of cells that stained
positive: < 10% is 1; 11 to 50% is 2; 51 to 75% is 3;
> 75% is 4. The final score was determined by multiplying
the intensity of positivity and the extent of positivity
scores, which yielded a range from 0 to 12. Expression of
CD133 and KAI1/CD82 were considered positive when
the scores were ≥ 3.
The positive expression of CD133 was found mainly
on the membrane and cytoplasm of LSCC cells and nor-
mal laryngeal tissues. The positive expression of KAI1/
CD82 was found mainly on the membrane and cyto-
plasm of LSCC cells and normal laryngeal tissues. They
were presented as a brown granular material.
Statistical analysis
Fisher’s exact test, Pearson Chi-square test for trends in
proportions, Spearman’s correlate analysis, and Kaplan-
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method for univariate or multivariate OS analysis were
used to assess the associations among the positive stain-
ing of CD133 or KAI1/CD82 and clinicopathological in-
dices. SPSS 17.0 software for windows (Chicago, IL,
USA) was used for this purpose. A value of P < 0.05 was
considered statistically significant.
Results
The association between the expression of CD133 or
KAI1/CD82 and clinicopathological factors
CD133 protein was expressed positively in 49.4% (41/83)
of LSCC and 4.8% (4/83) of normal laryngeal tissues.
There was a significant difference between the LSCC group
and the normal laryngeal tissues (P < 0.01) (Figure 1A and
B). There was a positive relationship between the expres-
sion of CD133 and histological grade, pTNM stage, and
lymph node metastasis (P < 0.05). The positive expression
of KAI1/CD82 was 41.0% (34/83) in the LSCC group and
96.4% (80/83) in normal laryngeal tissues. A significant dif-
ference was found between the LSCC group and the
normal group (P < 0.05) (Figure 2A and B). There was a
negative relationship between the expression of KAI1/
CD82 protein and alcohol, histological grade, pTNM
stage, and lymph node metastasis (P < 0.05). However, the
expression of CD133 and KAI1/CD82 was not associated
with gender, age, tumor localization, smoking, and tumor
diameter (P > 0.05) (Table 1).
Prognosis and multivariate analysis
Follow-up data showed that the OS rate and DFS rate
for CD133-positive patients were significantly poorer
than that of CD133-negative patients (P < 0.001, P < 0.001,
Figure 3). Also, there was a significantly increasing trend
in the mean OS survival time and DFS time between the
carcinomas with the expression of KAI1/CD82 and those
without (P < 0.001, P < 0.001, Figure 4). In the 83 LSCC
patients, a univariate analysis (Table 2) revealed that the
DFS survival significantly correlated with expression ofFigure 1 Expression of CD133 protein in laryngeal squamous cell carc
cancer cells (CD133 × 400). (B) CD133 was expressed as positive in the memCD133 (P < 0.001) and KAI1/CD82 (P < 0.001), tumor lo-
cation (P = 0.033), grade of tumor (P = 0.002), lymph node
metastasis (P = 0.004), and pTNM stages (P < 0.001). A
multivariate analysis revealed expression of CD133 and
KAI1/CD82, lymph node metastasis, and pTNM stages
were independent prognostic factors for DFS and OS
(P < 0.05) (Tables 3 and 4).Correlation of CD133 and KAI1/CD82 in LSCC
There was a negative correlation between CD133 ex-
pression and KAI1/CD82 expression in LSCC (r = −0.578,
P < 0.001).Discussion
Cancer stem cells (CSCs), also known as tumor initiating
cells (TICs), are a subpopulation of tumor cells with the
stem cell capacity for self-renewal. They give rise to the
differentiated cells, and generate the heterogeneous line-
ages of cancer cells that comprise the bulk of the tumor
[2,7,11,20,34-39]. CSCs may originate by malignant trans-
formation of normal stem cells or arise from restricted
progenitors of more differentiated cells [40]. The protein
CD133 is one of the hot CSC markers in a variety of tu-
mors [7-20]. In this study, we found that the positive ex-
pression of CD133 was 49.4% in LSCC patients. The study
investigated the expression of CD133 protein in 83 LSCC
specimens with follow-up data and the results indi-
cated that CD133 protein expression level was posi-
tively correlative with grade of tumor (P = 0.001), lymph
node metastasis (P < 0.001), and pTNM stage (P = 0.005).
Furthermore, we also found the expression of CD133 was
significantly associated with OS time (P < 0.001) and
DFS time (P < 0.001), suggesting the expression of CD133
might be a potential prognostic factor in LSCC. Another
result is that not only LSCC cell express CD133 but also
normal laryngeal tissue (squamous epithelial cells). This
indicated that CD133 might play an important role in
tumorigenesis [8].inoma. (A) CD133 was expressed as positive in the membrane of
brane of cancer cells at the invasive cancer (CD133 × 400).
Figure 2 Expression of KAI1/CD82 protein in laryngeal squamous cell carcinoma. (A) KAI1/CD82 was expressed as positive in the
membrane of cancer cells (KAI1/CD82 × 400). (B) KAI1/CD82 was expressed as positive in membrane and cytoplasm of cancer cells (KAI1/CD82 × 400).
Table 1 Correlation of CD133 and KAI1/CD82 expression to clinicopathogical characteristics in laryngeal squamous cell
carcinoma (LSCC)
Variable CD133 P-value KAI1/CD82 P-value
Negative Positive Negative Positive
Gender > 0.05 > 0.05
Male 36 39 46 29
Female 6 2 3 5
Age > 0.05 > 0.05
< 60 15 12 15 12
≥ 60 27 29 35 22
Location > 0.05 > 0.05
Supraglottic 26 25 26 25
Glottic 15 14 20 9
Subglottic 1 2 3 0
Diameter of tumor > 0.05 > 0.05
< 2.0 cm 23 20 22 21
≥ 2.0 cm 19 21 27 13
Smoking > 0.05 > 0.05
No 18 13 15 16
Yes 24 28 34 18
Alcohol > 0.05 < 0.05
No 20 13 14 19
Yes 22 28 35 15
Grade of tumor < 0.01 < 0.001
Well-differentiated 23 7 9 21
Moderately-differentiated 18 29 35 12
Poorly-differentiated 1 5 5 1
Lymph node metastasis < 0.001 < 0.01
No 33 16 23 26
Yes 9 25 26 8
pTNM stage < 0.05 < 0.05
I and II 33 20 26 27
III and IV 9 21 23 7
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Figure 3 Kaplan-Meier survival analysis by CD133 status (n = 83). (A) The green line represents the CD133-positive group patients with a
trend of worse survival than the blue line representing CD133-negative group patients (log-rank = 40.949, P = 0.000). Mean overall survival (OS)
time was 42.4 months for the CD133-positive group and 73.3 months for the CD133-negative group. (B) The green line represents CD133-positive
group patients with a trend of worse survival than the blue line representing CD133-negative group patients (log-rank = 39.307, P = 0.000). Mean DFS
for patients was 37.1 months for the CD133-positive group and 65.6 months for the CD133-negative group.
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useful marker for the metastatic and prognostic potential in
a series of human tumors. The precise mechanism for the
regulation of KAI1/CD82 is unclear. But, in the progression
of many tumors, the most common mechanism was down-
regulation or loss-regulation rather than mutation [22,24].
Our study results showed that KAI1/CD82 was negatively
associated with grade of tumors (P < 0.001), lymph node
metastasis (P = 0.007), and pTNM stage (P = 0.014). FromFigure 4 Kaplan-Meier survival analysis by KAI1/CD82 status (n = 83).
with a trend of better survival than the blue line representing the KAI1/CD
survival (OS) time was 76.0 months for the KAI1/CD82-positive group and 4
represents the KAI1/CD82-positive patient group with a trend of better sur
patients (log-rank = 39.271, P = 0.000). Mean DFS patients was 68.0 months
negative group.further research, we found that the KAI/CD82-positive-
group correlated with longer survival time, a result which
was in agreement with previous reports [32,41,42].
Our research also showed that CD133 expression was
negatively correlated with KAI1/CD82 expression
(P < 0.001). CSCs can manipulate stromal cells to their
needs in distant organs and thus prime the foreign soil for
their arrival by inducing a premetastatic niche [43]. This
indicates that CSCs have high migratory potential and(A) The green line represents the KAI1/CD82-positive patient group
82-negative patient group (log-rank = 40.279, P = 0.000). Mean overall
5.5 months for the KAI1/CD82-negative group. (B) The green line
vival than the blue line representing the KAI1/CD82-negative group
for the KAI1/CD82-positive group and 40.1 months for the KAI1/CD82-
Table 2 Results of univariate analyses of disease-free survival (DFS) and overall survival (OS) time
Variable n Mean DFS P-value Mean OS P-value
(months) (months)
CD133 < 0.001 < 0.001
+ 41 42.4 ± 18.2 37.1 ± 17.7
̶ 42 73.3 ± 16.7 65.6 ± 15.4
KAI1/CD82 < 0.001 < 0.001
+ 34 76.0 ± 19.3 68.0 ± 17.5
̶ 49 45.5 ± 16.8 40.1 ± 16.7
Gender 0.035 0.067
Male 75 56.4 ± 23.0 50.0 ± 21.9
Female 8 73.1 ± 21.9 65.6 ± 17.0
Age 0.854 0.280
< 60 27 58.2 ± 21.5 50.9 ± 19.5
≥ 60 56 57.9 ± 24.3 51.8 ± 23.0
Location 0.004 0.065
Supraglottic 51 60.3 ± 24.1 53.9 ± 22.5
Glottic 29 56.4 ± 21.8 49.6 ± 20.5
Subglottic 3 35.0 ± 13.7 29.3 ± 11.2
Diameter of tumor 0.015 0.217
< 2.0 cm 43 65.5 ± 19.5 58.5 ± 18.5
≥ 2.0 cm 40 50.0 ± 24.6 44.0 ± 22.9
Smoking 0.122 0.132
No 31 62.0 ± 26.4 55.3 ± 22.4
Yes 52 55.6 ± 21.2 49.3 ± 20.1
Alcohol 0.365 0.163
No 33 62.4 ± 24.1 54.9 ± 22.5
Yes 50 55.1 ± 22.6 49.2 ± 21.3
Grade of tumor < 0.001 0.009
Well-differentiated 30 71.7 ± 18.7 64.4 ± 17.6
Moderately-differentiated 47 50.4 ± 22.1 44.5 ± 20.7
Poorly-differentiated 6 49.3 ± 25.3 42.2 ± 22.8
Lymph node metastasis < 0.001 0.003
No 49 67.6 ± 18.9 60.5 ± 17.4
Yes 34 44.2 ± 22.4 38.6 ± 21.3
pTNM < 0.001 < 0.001
I and II 53 68.3 ± 19.2 61.3 ± 17.4
III and IV 30 40.0 ± 18.4 34.3 ± 18.0
Table 3 Results of multivariate analyses of disease-free
survival (DFS) time
Covariate B SE Sig Exp(B) 95%CI
CD133 0.747 0.354 0.035 2.110 1.055 to 4.221
KAI1/CD82 −1.282 0.432 0.003 0.278 0.119 to 0.647
pTNM 1.203 0.350 0.001 3.331 1.678 to 6.611
Lymph node metastasis 0.643 0.291 0.027 1.903 1.075 to 3.366
Table 4 Results of multivariate analyses of overall
survival (OS) time
Covariate B SE Sig Exp(B) 95%CI
CD133 0.734 0.351 0.037 2.083 1.046 to 4.146
KAI1/CD82 −1.486 0.449 0.001 0.226 0.094 to 0.545
pTNM 1.191 0.349 0.001 3.292 1.659 to 6.530
Lymph node metastasis 0.747 0.287 0.009 2.110 1.203 to 3.701
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of KAI1/CD82 may further promote the metastatic ability
of CSCs. Although the precise molecular mechanism in-
volved in this process is unclear, our research has potential
clinical benefits. CD133 and KAI1/CD82 expression,
which could be detected by immunohistochemistry, might
be a useful molecular marker to predict the prognosis in
LSCC patients. It is concluded that the expression of
CD133 and KAI1/CD82 protein could be correlated with
lymph node metastasis, grade of tumor, and pTNM stage
in LSCC, and also concluded that they are useful prognos-
tic factors for OS and DFS in LSCC. The combined detec-
tion of CD133 and KAI1/CD82 can, to some extent,
reflect the biological behavior of LSCC, thus giving the
choice of molecular targeting therapy. However, the num-
ber of specimens in our study was relatively small. Further
studies with larger sized specimens and molecular experi-
ments are needed to verify the present observations.
Conclusions
It is suggested that CD133 and KAI1/CD82 may play an
important role in the evolution of LSCC. And CD133
and KAI1/CD82 should be considered as potential marker
for the prognosis in patients with LSCC.
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